RNL 26 Report: RA-ILD Save
Audrey Gibson, PA-C, reports from RheumNow Live 2026 in Dallas, Texas, on the lecture, "ILD in RA - Recent Advances" given by Dr. Jeffrey Sparks.
Transcription
Hi, I'm Audrey Gibson. I'm a physician assistant from Gainesville, Georgia, and I'm reporting live from RheumNow Live in Dallas, Texas.
During this morning's presentations, Dr. Sparks gave a wonderful presentation on rheumatoid arthritis and ILD. He reviewed the recent advancements in rheumatoid arthritis-associated interstitial lung disease, an increasingly recognized and clinically important complication of RA.
RA-ILD is more common than many clinicians realize. Long-term population studies suggest that nearly one in six patients with RA will develop ILD over time, and its prevalence appears to be increasing. Unlike many other RA outcomes, mortality related to RA-ILD has not improved in the biologic era, making early recognition and management critical.
Several key factors consistently emerge. These include male sex, older age at RA diagnosis, smoking, higher inflammatory burden, and high rheumatoid factor or anti-CCP titers. Genetics also play an important role, particularly the MUC5B promoter variant, which is strongly associated with RA-ILD, especially the UIP pattern, the most common and poorest prognosis subtype seen in RA.
Importantly, RA disease activity matters. Higher DAS-28 scores over time were associated with increased risk of developing ILD, reinforcing the concept that systemic inflammation contributes directly to lung disease risk, not just joint damage.
Screening was a major focus that Dr. Sparks discussed today. The recent 2023 ACR and CHEST guidelines recommended targeted screening rather than universal high-resolution CT scanning, using clinical risk factors to identify patients most likely to benefit. Emerging risk scores, including those incorporating genetics, show promise in improving specificity and identifying subclinical RA-ILD earlier in the disease course.
Outcomes remain concerning. RA-ILD is associated with significantly increased mortality, particularly in patients with UIP, reduced TLCO, or more extensive fibrosis. About one-third of patients experience progression within 3 years, highlighting the need for close monitoring. Treatment options are evolving but evidence remains limited.
Thanks for tuning in from RheumNow Live. We've got more expert insights on the way, so stay tuned.
During this morning's presentations, Dr. Sparks gave a wonderful presentation on rheumatoid arthritis and ILD. He reviewed the recent advancements in rheumatoid arthritis-associated interstitial lung disease, an increasingly recognized and clinically important complication of RA.
RA-ILD is more common than many clinicians realize. Long-term population studies suggest that nearly one in six patients with RA will develop ILD over time, and its prevalence appears to be increasing. Unlike many other RA outcomes, mortality related to RA-ILD has not improved in the biologic era, making early recognition and management critical.
Several key factors consistently emerge. These include male sex, older age at RA diagnosis, smoking, higher inflammatory burden, and high rheumatoid factor or anti-CCP titers. Genetics also play an important role, particularly the MUC5B promoter variant, which is strongly associated with RA-ILD, especially the UIP pattern, the most common and poorest prognosis subtype seen in RA.
Importantly, RA disease activity matters. Higher DAS-28 scores over time were associated with increased risk of developing ILD, reinforcing the concept that systemic inflammation contributes directly to lung disease risk, not just joint damage.
Screening was a major focus that Dr. Sparks discussed today. The recent 2023 ACR and CHEST guidelines recommended targeted screening rather than universal high-resolution CT scanning, using clinical risk factors to identify patients most likely to benefit. Emerging risk scores, including those incorporating genetics, show promise in improving specificity and identifying subclinical RA-ILD earlier in the disease course.
Outcomes remain concerning. RA-ILD is associated with significantly increased mortality, particularly in patients with UIP, reduced TLCO, or more extensive fibrosis. About one-third of patients experience progression within 3 years, highlighting the need for close monitoring. Treatment options are evolving but evidence remains limited.
Thanks for tuning in from RheumNow Live. We've got more expert insights on the way, so stay tuned.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.